After Aurora Cannabis’ Announcement This Week, is the Stock a Buy?

: ACB | Aurora Cannabis Inc. Common Shares News, Ratings, and Charts

ACB – Aurora Cannabis (ACB) recently announced it will need more money to finance operations and an analyst changed his tune on the stock. Does this provide a buying opportunity? Read more to get Aaron Missere’s thoughts.

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Since Aurora Cannabis (ACB) announced its most recent earnings, the stock has been moving lower. Shares of the Canadian cannabis producer have lost almost 50% of their value in just a few weeks. 

A couple of days ago, the company added more kindle to the fire by revealing it has been burning through its cash faster than it had anticipated and will need to raise an additional $500 million over the next 25 months.

Management said in a press release on Tuesday that it only had $272 million left in proceeds from its at-the-market (ATM) program. This means that the company has used what was left of the $183M equity facility in the last 30 days. Now the company is proposing to sell $500 million of common shares, preferred shares, warrants, subscription receipts and debt securities.

Pablo Zuanic, an analyst at Cantor Fitzgerald who had previously remained optimistic on ACB despite their ongoing struggles, cut his estimates. Zuanic lowered his 12-month price target on ACB to just $7 from a staggering $18. He also reduced his rating from “overweight” to “neutral” while calling the news on Tuesday “contrary to expectations and guidance.”

I was surprised Zuanic kept his overweight rating over the past month, as ACB announced a string of bad news which included the departure of Nelson Peltz. Zuanic stated that the downgrade was long overdue.

Owen Bennett, an analyst from Jefferies, said, “It’s unsurprising the company is looking to raise funds.” He also stated that, “Even if Aurora hit its latest target of achieving positive EBITDA in fiscal 2021, the company was at risk of under-investing in the business without raising additional funds.”

Bennet noted on Monday that, “What is surprising is the size of the possible raise and the dilution that comes with this. Exhaustion of the ATM would have already represented [approximately] 26 percent dilution, while full use of the US$500 million would be an additional [approximately] 50 percent based on the current share price.”

These figures are very hard to stomach for investors who have stuck with the company for so long knowing that they could face another potential 50% downside. Many retail investors are down substantially on their position in ACB, which has created a series of class-action lawsuits against the company in recent months. 

Bennet went on to voice his opinion on how ACB should position themselves, “It needs to establish a strong CBD business, and U.S. infrastructure, ahead of this, and then be prepared to invest in cannabis if any laws change. With most institutional money likely to be focused on U.S. names should we see legalization, if Canadian names can’t argue a strong case for competitiveness, they may struggle to catch a bid.”

At this point, I believe that ACB needs to focus on profitability and continue to cut SG&A expenses. If the company can continue to strengthen its balance sheet and prove to investors that they can generate consistent revenues, the stock might have a chance at stabilizing.

However, as the situation stands right now, ACB remains a high risk investment in my opinion and investors may want to watch from the sidelines for the time being. 

(Disclosure: The author is long ACB)

Want More Great Investing Ideas?

Why is the Stock Market Tanking Now?

7 Best ETFs for the NEXT Bull Market

5 WINNING Stocks Chart Patterns


ACB shares rose $0.09 (+2.35%) in premarket trading Thursday. Year-to-date, ACB has declined -85.22%, versus a 2.95% rise in the benchmark S&P 500 index during the same period.


About the Author: Aaron Missere


Aaron is an experienced investor who is also the CEO of Departures Capital. His primary focus is on the cannabis industry. He also hosts a weekly show on YouTube about marijuana stocks. Learn more about Aaron’s background, along with links to his most recent articles. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
ACBGet RatingGet RatingGet Rating

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Investors: We Have Much to Be Thankful For!

The stock market (SPY) continues to press higher even in the midst of a national escalation in Covid-19 cases. That is because the market is a forward looking mechanism that puts more weight into the benefit of upcoming vaccines instead of the 2nd wave taking place now. On top of that Steve Reitmeister will spell out his strategy to outperform in the weeks and months ahead. Read on for the full story...

:  |  News, Ratings, and Charts

The 3 Best Stocks to Buy for December

We have one month left in this historic year. For many people, December means cold weather, holidays, and eating. The following three stocks should see potential gains next month based on those three December trends: Walmart (WMT), The Hershey Company (HSY), and Canada Goose Holdings Inc. (GOOS).

:  |  News, Ratings, and Charts

4 "Buy Rated" Clean Energy Stocks to Invest in for 2021

With federal governments across the world boosting clean energy, stocks like NIO (NIO), First Solar (FSLR), Canadian Solar (CSIQ) and Renewable Energy (REGI) should witness significant growth in the upcoming months.

:  |  News, Ratings, and Charts

Are Shares of CVS Still a Buy After the Launch of Amazon Pharmacy?

The public health crisis has accelerated CVS Health’s (CVS) transformation from a pharmacy and retailer into a health insurance and healthcare supplier. Its recent decline due to the launch of Amazon Pharmacy, could be a buying opportunity.

:  |  News, Ratings, and Charts

4 "Buy Rated" Clean Energy Stocks to Invest in for 2021

With federal governments across the world boosting clean energy, stocks like NIO (NIO), First Solar (FSLR), Canadian Solar (CSIQ) and Renewable Energy (REGI) should witness significant growth in the upcoming months.

Read More Stories

More Aurora Cannabis Inc. Common Shares (ACB) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ACB News